Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Adverse Effects, Drugs Clinical Trials

A listing of Adverse Effects, Drugs medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (51) clinical trials

A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition Memory and Tremor) in Elderly (Age>65) Patients

The investigators will conduct a single-center, prospective, open-label, randomized study to evaluate the difference in neurocognitive side effects between Envarsus and immediate release tacrolimus. Eligible patients will be enrolled within 8 weeks post-transplantation. They will be administered a baseline panel of neurocognitive tests. They will then be randomized to either ...

Phase

Post-market Safety Reassessment of Ulinastatin for Injection

In order to find out the application of ulinastatin in real practice clinic , identify the high risk group for adverse event/adverse drug reaction and calculate the adverse event/adverse drug reaction incidence rate, a large sample size clinical trial has been designed. This trial is an observational study. The investigators ...

Phase N/A

Discontinuation of Long-term Medications in Older People Entering Nursing Home Care

STUDY TITLE Medication Rationalization for Older People awaiting long-term nursing home care: a randomized controlled trial using the STOPPfrail criteria. AIMS Our primary aim is to test the feasibility of applying explicit deprescribing criteria (STOPPfrail) to the medication regimens of a cohort of older, frail hospitalized patients for whom long-term ...

Phase N/A

Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity

Drug-induced liver injury (DILI), especially its idiosyncratic for is often an unpredictable complication of drug therapy. Until now it is very challenging to predict occurrence, severity and outcome of DILI. Previous data provide evidence that cells from peripheral blood may reflect hepatocellular damage (Fannin RD, Hepatology. 2010). Own research could ...

Phase N/A

Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide

The majority of HIV-1 infected patients in resource rich countries receive the tenofovir prodrug tenofovir disoproxil fumarate (TDF) as part of their combination antiretroviral therapy (cART). Long-term exposure to TDF can be associated with an accelerated estimated glomerular filtration rate (eGFR) decline and proximal renal tubular dysfunction (PTD, see definition ...

Phase

Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens

The purpose of this study is to determine whether the addition of selective pharmacogenomic (PGx) testing as determined by Urine Drug Testing (UDT) adds a clinical benefit as evidenced by a reduction in Target Drug-related Adverse Events (TDRAE) over the period following enrollment.

Phase

Individualized Optimal Therapy of Antipsychotics

Schizophrenia is a serious mental disease that threaten human health, the lifetime prevalence rate of about 1%, the current Chinese schizophrenia patients nearly 10 million people, antipsychotic drugs is the main method in the treatment of schizophrenia, but the efficacy and safety of individual differences, about 1/3 in drug treatment ...

Phase N/A

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study

Toxic epidermal necrolysis (TEN) is a potentially life-threatening skin disorder characterized by widespread redness, blistering and peeling of skin. Currently, supportive care in the standard treatment for patients with TEN. Isotretinoin, an FDA-approved medication commonly used for treating severe acne induces differentiation of certain inflammatory cells and thus may potentially ...

Phase N/A

High-Dose Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

To evaluate the efficacy and safety by treating the advanced non small cell lung cancer (NSCLC) patients who have failure of standard dose EGFR-TKIs(Erlotinib or Gefitinib ) with high-dose, pulsatile Erlotinib(450mg every 3 days) or Gefitinib (1000mg every 4 days)

Phase

Impact of Clinical Pharmacist on Adverse Drug Events in Older Adults

The intervention plan during hospitalization will consist of daily monitoring of pharmacological efficacy and safety, participating in clinical rounds and patient interviews. To review, assess the indications according to the conditions of each patient and evaluating possible interactions of clinical importance, dose adjustments, potentially inappropriate medication for older adult (OA), ...

Phase N/A